Atlas Trials

MedImmune LLC

270 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch MedImmune LLC

RecordFirmDate
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC (NCT04145193)MedImmune LLC2020-10-01
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (NCT04522323)MedImmune LLC2020-08-05
Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza (NCT03903718)MedImmune LLC2020-04-03
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (NCT04261075)MedImmune LLC2020-03-03
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors (NCT03889275)MedImmune LLC2019-10-24
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide (NCT04091373)MedImmune LLC2019-09-27
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. (NCT04019561)MedImmune LLC2019-09-23
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (NCT04068610)MedImmune LLC2019-09-13
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors (NCT03946800)MedImmune LLC2019-05-08
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer (NCT03794544)MedImmune LLC2019-03-08
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus (NCT03745937)MedImmune LLC2019-01-07
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (NCT03811652)MedImmune LLC2018-12-20
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (NCT03822351)MedImmune LLC2018-12-19
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus (NCT03654313)MedImmune LLC2018-09-28
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus (NCT03596177)MedImmune LLC2018-09-26
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants (NCT03625778)MedImmune LLC2018-08-14
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated (NCT03550378)MedImmune LLC2018-06-29
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (NCT03611556)MedImmune LLC2018-06-21
D2560C00015 FluMist Annual Safety Study 2018 (NCT03564444)MedImmune LLC2018-06-06
A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction (NCT03578809)MedImmune LLC2018-06-05
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. (NCT03555994)MedImmune LLC2018-05-31
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes (NCT03444584)MedImmune LLC2018-05-08
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (NCT03381274)MedImmune LLC2018-05-08
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (NCT03489525)MedImmune LLC2018-05-08
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (NCT03530397)MedImmune LLC2018-04-24
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent (NCT03385369)MedImmune LLC2018-01-05
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease (NCT03351738)MedImmune LLC2017-12-13
A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses (NCT03362593)MedImmune LLC2017-12-04
A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382 (NCT03341013)MedImmune LLC2017-11-30
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382 (NCT03347968)MedImmune LLC2017-11-27
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects (NCT03235375)MedImmune LLC2017-10-27
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. (NCT03244800)MedImmune LLC2017-09-04
Next →

Track MedImmune LLC automatically

Every clearance here is in the API, with alerts when new ones post.